Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cann GroupASX:CAN -14.29% Days Sales Outstanding is 29.37 as of Dec. 2025, which is 78% below its 10-year median of 131.10. The stock has 7 warning signs investors should review. Among 946 Drug Manufacturers companies, Cann Group ranks better than 77.38% on this metric.
Cann Group's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$0.73 Mil. Cann Group's Revenue for the
six
months ended in Dec. 2025 was A$4.52 Mil.
Hence, Cann Group's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 29.37.
The historical rank and industry rank for Cann Group's Days Sales Outstanding or its related term are showing as below:
ASX:CAN'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.43 Med: 131.1 Max: 340.46
Current: 46.94
During the past 9 years, Cann Group's highest Days Sales Outstanding was 340.46. The lowest was 35.43. And the median was 131.10.
ASX:CAN's Days Sales Outstanding is ranked better than 77.38% of 946
companies
in the Drug Manufacturers industry
Industry Median: 71.98
vs ASX:CAN: 46.94
Cann Group's Days Sales Outstanding
declined
from Dec. 2024 (53.07) to Dec. 2025 (29.37).
Cann Group (ASX:CAN) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Cann Group Days Sales Outstanding Related Terms
Cann Group Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Cann Group's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cann Group Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cann Group's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Cann Group's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cann Group (ASX:CAN) has a Days Sales Outstanding of 29.37 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cann Group and its competitors. This is 78% below median its historical median of 131.10. Over the past decade, Cann Group's Days Sales Outstanding has ranged from 35.43 to 340.46. According to the industry distribution chart, Cann Group ranks #214 out of 946 companies in the Drug Manufacturers industry, placing it in the top 22.6%.
Is Cann Group's Days Sales Outstanding too high?
Cann Group's current Days Sales Outstanding of 29.37 is 78% below median its 10-year median of 131.10. Over the past 10 years, this metric has ranged from a low of 35.43 to a high of 340.46. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. Cann Group's value of 29.37 is 59.2% below this industry median. Based on the distribution chart, Cann Group ranks #214 out of 946 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Cann Group's Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cann Group ranks #214 out of 946 companies for Days Sales Outstanding. This places Cann Group in the top 23% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 71.98. Cann Group's value of 29.37 is 59.2% below this benchmark. Historically, Cann Group's own Days Sales Outstanding has ranged from 35.43 to 340.46 over the past decade. While the company's 10-year median is 131.10 vs. the industry median of 71.98, Cann Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cann Group's current Days Sales Outstanding of 29.37 is 59.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cann Group and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cann Group's current Days Sales Outstanding is 29.37, which is 78% below median its own 10-year median of 131.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cann Group stock overvalued right now?
Based on GuruFocus' analysis, Cann Group (ASX:CAN) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 85% below its estimated fair value. The current Days Sales Outstanding is 29.37, which is 78% below median its 10-year median of 131.10 and 59.2% below the Drug Manufacturers industry median of 71.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Cann Group (ASX:CAN), the current Days Sales Outstanding is 29.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CAN has been successfully added to your 
